Tocilizumab to prevent side effects from ramantamig in multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This study tests whether a drug called tocilizumab can prevent serious side effects (cytokine release syndrome) when combined with a new cancer drug called ramantamig. You'll be eligible if you have multiple myeloma that has come back or stopped responding to prior treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with multiple myeloma and have measurable disease
- You have received at least one prior cancer treatment for myeloma
- Your myeloma has relapsed (came back after initial response) or is refractory (didn't respond or stopped responding to treatment)
- You are generally able to care for yourself, with a performance status score of 0–2
- Your blood work and organ function meet study requirements
- You are not currently receiving other cancer treatments and have not had major surgery within the past 2 weeks
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests two antibody medicines (teclistamab or talquetamab) given as outpatient injections, to treat multiple myeloma. It also tests preventing and treating side effects with supportive medicines, aiming to improve disease control in people who have already tried other myeloma treatments.
This trial tests a new combination of two drugs, ramantamig and daratumumab, against other standard treatments for people newly diagnosed with multiple myeloma who are not planning to have a stem cell transplant. The goal is to see if this combination works better at controlling the cancer.
This study tests a new drug called elranatamab given as outpatient infusions for multiple myeloma that has come back or stopped responding to prior treatments. The drug is designed to help your immune system fight the cancer cells.
This trial tests a combination of two drugs—teclistamab (an immunotherapy) and mezigdomide (a targeted pill)—for people with multiple myeloma that has come back or not responded to previous treatments. The goal is to see if this new combination can help when other options have stopped working.
This study tests whether a drug called sirolimus, given before certain immunotherapy treatments (teclistamab or talquetamab), helps these treatments work better against multiple myeloma. These immunotherapies teach your immune cells to attack myeloma cells.
This study looks at how well two newer medicines, teclistamab and talquetamab, work in people with multiple myeloma that has come back or stopped responding to several treatments. If you qualify, you may be able to receive one of these medicines as part of your regular care.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.